Advisory Board

Advisory Board

Dr Ian Fotheringham - Ingenza

Dr Ian Fotheringham - Ingenza


Ian Fotheringham received a Ph.D. in Molecular Biology from the University of Glasgow, UK in 1986.

With the NutraSweet division of Monsanto in Chicago, USA, he then engineered microbes to produce the Aspartame® sweetener, in one of the first and largest scale successes of synthetic biology. From 1993 he continued developing large scale bioprocesses with NSC Technologies and Great Lakes Fine Chemicals.

In 2003, he co-founded Ingenza, an Edinburgh, UK, based SME, now a leading Industrial Biotechnology and Synthetic Biology company. Ingenza is providing a new generation of manufacturing technologies to industries worldwide, focusing on sustainable and ethical raw materials and the use of fermentation based processes.
Dr Mike Goosey

Dr Mike Goosey

Mike is a bioenergy and industrial biotechnology consultant and is an honorary Professor in Sustainable Bioenergy at the University of Nottingham. He is a council member for the BBSRC.  Mike was previously with the Royal Dutch Shell Company for 21 years. He served as Global Manager for Shell's R&D Biofuels Programme in Shell’s Alternative Energies business.  In this role, he led multi-disciplinary R&D teams in the Americas, Europe, and SE Asia, both within Shell, Universities, Institutes, and in partnerships with biotechnology startups such as  Iogen, Codexis, Cellana, and Virent.

In his previous assignments, he was the Global Manager for Pervasive R&D Technologies, supporting Shell's Refinery operations, LNG, and Chemicals businesses. His team also provided trackside support for the Ferrari F1 team. Previous to this, he was responsible for the biochemical and molecular biology team at Sittingbourne Research Centre, UK involved in the molecular design of Agrochemicals.

Mike has a PhD in Biochemistry and was a Parkinson's  Disease Research Fellow at the Medical School, Birmingham University, UK, before joining Dow Chemical Company where he worked for 6 years in the Agrochemical Business. Mike was made a Fellow of the Royal Society Of Chemistry in 2007.

Robin Higgons - Qi3

Robin Higgons - Qi3


As Managing Director of Qi3, Robin is a specialist in international technology marketing at the highest level, focusing on strategy, marketing, sales, and technology translation. His private clients range from large corporations such as Unilever, Lockheed Martin, Selex, and Elekta, through SMEs and Venture Capital Funds, to start-up companies. In the public sector, Robin has led major market evaluation and engagement projects for the European Space Agency, UK Space Agency, and the Technology Strategy Board. His academic clients include UK Research Councils, and a wide range of Universities. He is a Steering Committee Member for the Centre for Doctoral Training in Science & Technology for Arts Heritage and Archaeology (SEAHA).
 
Robin has a long track record of success in finding and exploiting new markets, launching disruptive new products, rapidly growing market share, and increasing profitability through market driven change.  In previous roles, Robin has extensive experience of marketing, sales, and general management in a broad range of global corporations including Air Products, Raychem, Pall, Oxford Instruments, and Halma.
 
In his spare time, Robin is a keen choral singer and Chairman of the Fairhaven Singers (www.fairhavensingers.org.uk).
Dr Steve Martin - Isomerase Therapeutics

Dr Steve Martin - Isomerase Therapeutics


Steve is currently Chief Business Officer for Isomerase Therapeutics and Director of IB consultancy company, Inspire Biotech. Steve has more than 25 years’ industrial experience in the development and commercialisation of biobased processes in the biotechnology and renewable fuels/chemicals sectors.

Steve was formerly CEO of ZuvaSyntha Ltd, a UK SME developing a novel C1 fermentation platform delivering low cost routes to important chemical building blocks. Prior to this, Steve was R&D Director at TMO Renewables, developing a process to convert lignocellulosic biomass into fuels and chemicals. Whilst at TMO, Steve was part of the executive team which raised more than $60m in private financing and built one of the UK’s first demonstration facilities for cellulosic ethanol. Prior to TMO, Steve was Head of Fermentation at Cubist Pharmaceuticals and played a key role in the process development and scale-up for Cubicin® (daptomycin) – a highly successful first-in-class lipopeptide antibiotic.

Steve received a PhD in Microbiology (Surrey) and is a visiting lecturer at the University of Bath.
Hilary Worton - Aequus Research

Hilary Worton - Aequus Research

With over 25 years of experience in the life sciences industry, Hilary is a Senior Director of Aequus Research and is based in London.  Aequus Research provides highly effective market research to the healthcare industry, primarily the pharmaceutical sector.  Hilary's focus is on providing strategic insights and guidance to companies in the development and commercialization of pharmaceutical products.

Hilary has a keen interest in research projects in particular evaluating novel technologies, targeted therapies, and in lifecycle management evaluations.  Having worked with most of the top tier global pharma companies and many of the niche, specialist players, Hilary has a deep and rich network of contacts and specialists across the spectrum of the global pharmaceutical industry.  She also continues to be an active contributor to international healthcare industry associations, including EphMRA.

Share by: